Search

Sloan Kettering Institute scientists report new findings about a gene that helps regulate DNA methylation.

… Friday, April 9, 2021 The DNA in our genes contains the instructions needed to manufacture all of the proteins in our cells. These proteins, in turn, do the work that keeps our bodies functioning. Therefore, knowing how individual proteins get made can help us understand the causes of human disease,

For the first time, researchers have found an association between the makeup of the microorganisms in the body before a bone marrow transplant and a patient’s survival afterward.

… Sunday, December 2, 2018 Summary For the first time, researchers have found that having a healthy balance of microorganisms in the body before a bone marrow transplant is associated with higher survival rates after the transplant. Update: On February 27, 2020, Dr. Peled, Dr. van den Brink, and their

New MSK research suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient cancers; modified a bacteria-made compound to target mutant KRAS-driven cancers; and shed new light on brain metastasis in non-small cell lung cancer.

… Thursday, August 24, 2023 New research from  Memorial Sloan Kettering Cancer Center (MSK)  and the  Sloan Kettering Institute  — a hub for basic science and translational research within MSK — suggests a method for revealing DNA repair “scars” could help make treatment decisions in BRCA1- and BRCA2-deficient

A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on June 9. William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), served as corresponding author on this study, which met its primary endpoint of progression-free survival and showed a statistically significant improvement in overall survival. To arrange an interview with Dr. Tap, please email [email protected].

… Friday, June 10, 2016 A new drug is being shown to extend the lives of patients with advanced soft tissue sarcoma by almost a year. The results of a multicenter phase II trial evaluating the efficacy and safety of olaratumab in combination with doxorubicin chemotherapy was published in The Lancet on

Breast pathologist Edi Brogi explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease.

… Tuesday, November 14, 2017 Summary Edi Brogi, a breast pathologist, explains what patients should know about breast cancer diagnosis, second opinions, and promising new developments in treating some of the most aggressive forms of the disease. A breast cancer diagnosis often starts when a change is found

Meet Emily Herzlin, who teaches mindfulness and meditation at Memorial Sloan Kettering.

… Wednesday, October 25, 2017 Summary Emily Herzlin, who teaches meditation through MSK’s Integrative Medicine Service , offers insight into how it can help people with cancer, survivors, and caregivers. Can the simple acts of being still, noticing your thoughts, and focusing on your breath really be transformative

Nick Kroll, Seth Meyers, Amy Schumer, John Mulaney, and special guests hosted the one-night-only event, taking the stage to outwit blood cancers and raising a record-breaking $2.3 million to fuel Memorial Sloan Kettering Cancer Center’s mission of ending cancer for life.

… Tuesday, May 20, 2025 Comedy vs Cancer, the official comedy benefit show for blood cancer research at Memorial Sloan Kettering Cancer Center (MSK), returned to Jazz at Lincoln Center’s Frederick P. Rose Hall. The sold-out, one-night-only event raised over $2.3   million to support lifesaving blood cancer

The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.

… Friday, August 12, 2022 On August 11, 2022, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab deruxtecan (also known as T-DXd or Enhertu®) for the treatment of advanced non-small cell lung cancer (NSCLC) driven by mutant HER2. Trastuzumab deruxtecan was previously approved for

Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients.

… Wednesday, March 6, 2019 VIDEO | 03:47 Expanding Organ Preservation Surgery in Esophageal Cancer Daniela Molena, MD, Director, Esophageal Surgery Program, talks on expanding organ preservation surgery in esophageal cancer and the quest to pinpoint the elusive sentinel node in these patients. Video Details

At the 2016 American Association for Cancer Research (AACR) conference, there were clear signs that cancer treatment is evolving from a slash-and-burn method to a more precisely targeted, intelligent approach.

… Wednesday, April 20, 2016 Summary Genomic sequencing of tumors is allowing cancer researchers to tailor treatments to patients in a way that was previously not possible, allowing a more targeted, personalized approach to cancer care. Increasingly, the focus of research is on finding the right combination